Shaukat Shah
Internal Medicine · Stockton, CANPI 1740292028
Payments from drug & device makers
Across 78 payments — averaging $1452.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$78K
- Novartis$29K
- AbbVie$5K
- Johnson & Johnson$257
- Novo Nordisk$156
- Merck$111
- plus $473 from 15 others
Across 6 payments — averaging $153.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$921
What the payments were for
- Food & beverage$1,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $78,080 |
| Novartis | 4 | $28,796 |
| AbbVie(2 entities) | 7 | $5,461 |
| Johnson & Johnson | 7 | $257 |
| Novo Nordisk | 4 | $156 |
| Merck | 3 | $111 |
| Amgen | 3 | $75 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $31 |
| Lundbeck LLC | 1 | $25 |
| VBI Vaccine (delaware) Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$100
How this compares
$113,333 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 152 | $51,000 |
| XifaxanRifaximin | 27 | $40,400 |
| OzempicSemaglutide | 13 | $12,457 |
| JardianceEmpagliflozin | 28 | $10,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,092 |
| XareltoRivaroxaban | 16 | $5,130 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 230 | $4,972 |
| Atorvastatin Calcium | 354 | $4,351 |
| Pantoprazole Sodium | 152 | $3,799 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $3,187 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,936 |
| Potassium Chloride | 55 | $2,822 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $2,725 |
| Levetiracetam | 93 | $2,620 |
| Amlodipine Besylate | 275 | $2,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78,080 | $51,000152 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $40,40027 claims |
| Novo NordiskOzempic | $156 | $12,45713 claims |
| Boehringer IngelheimJardiance | $19 | $10,57928 claims |
| Johnson & JohnsonXarelto | $257 | $5,13016 claims |
| MerckJanumet | $111 | $2,72520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Stockton
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.